Improving Patient Outcomes: Prophylactic Options in Graft-Versus-Host Disease

Author(s):

Michael R. Bishop, MD, University of Chicago,Hannah Choe, MD

Panelists Hannah Choe, MD, and Bart L Scott, MD share insights concerning prophylaxis in Graft-Versus-Host Disease, including key study data and current standards of care as well as discuss the potential role of biomarkers in GvHD.

EP: 1.Understanding Chronic and Acute Graft-Versus-Host Disease Presentation and Diagnosis

Now Viewing

EP: 2.Improving Patient Outcomes: Prophylactic Options in Graft-Versus-Host Disease

EP: 3.Optimal First-Line Treatment Approaches for Acute GvHD

EP: 4.Treatment Options in Steroid-Refractory Acute GvHD

EP: 5.Enhancing Patient Care in Acute GvHD: Supportive Measures

EP: 6.Advancements and Promising Directions in Acute GvHD

EP: 7.Establishing Treatment Objectives for Chronic GvHD: First-Line Strategies

EP: 8.A Comprehensive Look at Initial Treatment Options for Chronic GvHD

EP: 9.Data-Driven Treatment Selection for Patients with Chronic GvHD

EP: 10.Remote Patient Monitoring and Supportive Care Measures in Chronic GvHD

EP: 11.The Future of Chronic GvHD Treatment

Latest Conference Coverage

Perioperative Pembrolizumab Regimen Upholds Survival Benefit in Resectable NSCLC

Zongertinib Elicits Durable Responses in Pretreated Advanced HER2-Mutant NSCLC

Lenvatinib Shows Efficacy in Advanced HCC Post-Progression on Atezolizumab/Bevacizumab

Sacituzumab Govitecan Does Not Significantly Improve OS in Pretreated Urothelial Carcinoma

View More Latest Conference Coverage

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Privacy

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512